Ionis begins clinical trial of antisense medicine for ALS treatment,

Ionis Pharmaceuticals has initiated a Phase III clinical trial of antisense medicine ION363 in patients with amyotrophic lateral sclerosis (ALS) with …, Ionis Pharmaceuticals has initiated a Phase III clinical trial of antisense medicine ION363 in patients with amyotrophic lateral sclerosis (ALS) with …, Read More

Scroll to Top